



Relationship between Cellular Senescence and Redox Potential on Adult T-Cell Leukemia Cells

Yasuhiro Maeda*, Atsushi Okamoto, Shin-ichiro Kawaguchi, Akiko Konishi, Kenta Yamamoto, Go Eguchi, and Terufumi Yamaguchi

Abstract

Human T-cell leukemia virus type I (HTLV-I) is a human retrovirus and an etiologic agent of adult T-cell leukemia/lymphoma (ATL/ATLL). The subtypes acute and lymphoma have a poor prognosis with median survival rate of approximately 6 months. Some excellent therapeutic strategies for ATL are required. Retinoids [all-trans retinoic acid (ATRA) and tamaribarotene (Am-80)] have been reported to inhibit the *in vitro* growth of HTLV-1 [+] T-cell lines and that of fresh cells obtained from patients with adult T-cell leukemia (ATL). We showed a clinical efficacy of retinoid therapy in treating ATL has also been evaluated. Further, we found that retinoid induced cellular senescence on ATL cells and tight relationship between cellular senescence and redox potential on ATL cells.

Keywords

HTLV-I; Retinoid; Senescence; ROS; Redox

Introduction

Human T cell leukemia virus type I (HTLV-I) is a human retrovirus that is an etiologic agent of adult T cell leukemia/lymphoma (ATL/ATLL) [1]. We previously reported the clinical efficacy of all-trans retinoic acid (ATRA) for patients with adult-T-cell leukemia (ATL) [2]. Additionally, we found that retinoids including ATRA could facilitate cellular senescence in HTLV-I-positive T-cell lines and fresh primary cells obtained from patients with acute ATL [3]. Cellular senescence was detected by staining for senescence-associated β -galactosidase (SA β -Gal) [4]. It is known that senescence is a well-established anti-cancer mechanism [5] and can be caused by telomere attrition, DNA damage, oncogene and oxidative stress [6].

In our previous study, significant cellular senescence was observed for *Tax* mRNA expressing cells (HUT102, MT-2, MT-4, and ATL-2 cells) than ED40515 cells, which do not express *Tax* mRNA because of a nonsense mutation [3]. Thus, we assume that *Tax* is an oncogene that could possibly be involved in oncogene-induced senescence (OIS) by retinoids. It has been reported that OIS does occur in human and mouse tumor cells *in vivo* [7,8]. Furthermore, it is caused by accumulation of DNA damage, which in turn causes oncogene-driven

accumulation of reactive oxygen species (ROS) [9]. Our hypothesis is that the *Tax* oncogene may induce cellular senescence via ROS, but the number of these senescing cells is easily reduced by retinoid. These results indicated that *Tax* mRNA expression may be a critical factor in retinoid therapy for patients with ATL and retinoid may be a reasonable agent for ATL with facilitating cellular senescence.

The balance of oxidative/anti-oxidative influences may play an important role in the modulation of cellular function. It has been reported that L-cysteine and L-cystine act as a buffer of the redox potential of the environment in cells or serum [10,11]. In our previous study, to study the effects of exogenous thiol compounds on the sensitivity to retinoid in a HTLV-I positive T cell line, ATL2 cells [12] were cultured with thiol compounds (L-cystine, GSH and TRX), following addition of ATRA or 13-*cis* RA [13,14]. Pre-incubation of ATL-2 with L-cystine or GSH resulted in complete restoration of growth despite the inhibitory effects of RA; this suggested that it helped to increase the redox potential of the intracellular environment [10]. These processes are antagonized by antioxidants such as cysteine and GSH [11]. Moreover, the effects of thiol compound, N-acetyl cysteine (NAC) for cellular senescence was examined. Figure 1 showed that spontaneous senescence was induced on HTLV-I positive T-cell lines (HUT102 and MT-2) but not on HTLV-I negative T-cell lines (Jurkat and MOLT-4). Furthermore, ATRA treatment induced more senescence on just HTLV-I positive T-cell lines. However, pretreatment with NAC for 24 hrs blocked cellular senescence by following addition with ATRA. These results suggest that the imbalance of intracellular redox potential in HTLV-I [+] T cell lines may be associated strongly with the sensitivity to RA and exogenous thiol compounds may prepare the intracellular environment to become resistant to RA. Further, pre-treatment with NAC for those cells was sufficient to recover from cellular senescence and finally rescue cell proliferation on HTLV-I positive T-lymphocytes. Having obtained those results described above, it has been suggested tight relationship between cellular senescence and redox potential on HTLV-I positive cells.




Figure 1: The effects of NAC for cellular senescence.

Note: Both HTLV-I positive cell lines [HUT102 and MT-2] and HTLV-I negative T-cell lines [Jurkat and MOLT-4] with 10⁻⁵ M NAC for 24 hrs were pre-incubated, and then 10⁻⁵ M ATRA was added to those cells for 24 hrs. Cellular senescence was detected by staining for senescence-associated β -galactosidase [SA β -Gal]. Values for the calculation were the mean of triplicate culture.

*Corresponding author: Yasuhiro Maeda, Department of Hematology, National Hospital Organization Osaka Minami Medical center, 2-1, Kido-Higashi, Kawachinagano, Osaka 586-8521, Japan, Tel: +81-721-53-5761; E-mail: ymaeda@ommc-hp.jp

Received: February 19, 2016 Accepted: March 16, 2016 Published: March 21, 2016

References

1. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H (1977) Adult T cell leukemia: Clinical and hematological features of 16 cases. *Blood* 50: 481-492.
2. Maeda Y, Yamaguchi T, Hijikata Y, Tanaka M, Hirase C, et al. (2008) Clinical efficacy of all-trans retinoic acid for treating adult T-cell leukemia. *J Cancer Res Clin Oncol* 134: 673-677.
3. Maeda Y, Sasakawa A, Hirase C, Yamaguchi T, Morita Y, et al. (2011) Senescence induction therapy for the treatment of adult T-cell leukemia. *Leuk Lymphoma* 52: 150-152.
4. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 92: 9363-9367.
5. Collado M, Blasco MA, Serrano M (2007) Cellular senescence in cancer and aging. *Cell* 130: 223-233.
6. Ben-Porath I, Weinberg RA (2005) The signals and pathways activating cellular senescence. *Int J Biochem Cell Biol* 37: 961-976.
7. Sakisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA (2007) Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. *Nat Cell Biol* 9: 493-505.
8. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. *Genes Dev* 21: 379-384.
9. Lee AC, Fenster BE, Ito H (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. *J Biol Chem* 274: 7936-7940.
10. Bannai S (1984) Transport of cystine and cysteine in mammalian cells. *Biochim Biophys Acta* 779: 289-306.
11. Miura K, Ishii T, Sugita Y, Bannai S (1992) Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress. *Am J Physiol* 262: C50-58.
12. Maeda M, Shimizu A, Ikuta K (1985) Origin of human T-lymphotropic virus I-positive T cell line in adult T cell leukemia. Analysis of T cell receptor gene rearrangement. *J Exp Med* 162: 2169-2174.
13. Miyatake J, Maeda Y, Sumimoto Y (1998) Thiol compounds rescue growth inhibition by retinoic acid on HTLV-I [+] T lymphocytes; possible mechanism of retinoic acid induced growth inhibition of adult T cell leukemia cells. *Hematopathol Mol Hematol* 11: 89-99.
14. Miyatake J, Maeda Y, Nawata H (2000) Important role of thiol compounds to protect oxidative stress on HTLV-I [+] T lymphocytes. *Leuk Res* 24: 265-266.

Author Affiliations

TOP

Department of Hematology, National Hospital Organization Osaka Minami Medical center, Osaka, Japan

Submit your next manuscript and get advantages of SciTechnol submissions

- ❖ 50 Journals
- ❖ 21 Day rapid review process
- ❖ 1000 Editorial team
- ❖ 2 Million readers
- ❖ More than 5000 
- ❖ Publication immediately after acceptance
- ❖ Quality and quick editorial, review processing

Submit your next manuscript at • www.scitechnol.com/submission